Gene-Therapy Company Crispr Drops as FDA Puts Trial on Hold – Bloomberg
Bloomberg |
Gene-Therapy Company Crispr Drops as FDA Puts Trial on Hold
Bloomberg Crispr is developing the therapy with Vertex Pharmaceuticals Inc., and the trial had yet to begin. The companies said in a statement Wednesday that the Food and Drug Administration placed a halt on the experiment until the agency could get more … What Makes This CRISPR Stock Better Than the Rest? FDA Halts Plan for Vertex, CRISPR Therapeutics Sickle Cell Study CRISPR Therapeutics and Vertex Provide Update on FDA Review of Investigational New Drug Application for CTX001 … |
